INCY — Incyte Corp. stock price and chart

INCY

Incyte Corp.Stock · HealthcareS&P 500 Equal Weight 0.2% · Nasdaq Composite 0.04% · S&P 500 0.03% · Russell 1000 0.03% · US Stock Market 0.03% · Russell 3000 0.02% · MSCI World 0.02% · MSCI ACWI 0.02%

$125.31-1.81%

as of market close, Sep 18, 2026

☾ AH — —

PeersMRNALLYUNHJNJMRKTMO

Technical analysis2

Overlay lines0

Addendum charts0

Volume

20162019202120242026

60.070.080.090.0100.0110.0120.0130.0140.0150.0020.0M40.0M$125.31

2026-09-18

Price$125.31

MA20$110.69

MA50$100.54

Vol8.1M

What would $1,000 invested in INCY be worth today? →

INCY returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $125.31
Change YTD: +26.87%
Next earnings: Oct 27, 2026
Market cap: 25.4B2016-09 17.8B2026-09 25.4B+43.0% over the window
Enterprise value: 21.5B
Shares outstanding: 202.7M2016-06 188M2026-06 202.7M+7.8% over the window
52W low: $81.09
52W high: $132.60
From 52W high: -5.50%
From 52W low: +54.53%
52W range: 86%
Beta: 0.76

Volume

Rel volume: 2.72×
30D volume: 1.4M
30D $ vol: 169.1M

Fundamentals

Sales (ttm): 5.8B2016-06 941.2M2026-06 5.8B+518.3% over the window
Sales/share: $28.712016-06 $5.012026-06 $28.71+473.5% over the window
EPS (ttm): $7.862016-06 $0.372026-06 $7.86+2023.0% over the window
FCF (ttm): 1.9B2016-12 184.5M2026-06 1.9B+941.0% over the window
FCF/share: $9.472016-12 $0.972026-06 $9.47+872.8% over the window
Book value/share: $31.302016-06 $1.582026-06 $31.30+1880.9% over the window
Net margin: 27.71%2016-06 7.9%2026-06 27.7%+252.1% over the window
ROE: 25.41%2016-06 24.9%2026-06 25.4%+1.9% over the window
ROA: 20.48%2016-06 5.2%2026-06 20.5%+292.1% over the window
Current ratio: 4.592016-06 3.982026-06 4.59+15.4% over the window

Growth (CAGR, ttm) · 10Y

Sales: +26.95%2025-06-30 → 2026-06-304.6B → 5.8B (+26.9% total)+18.32%2023-06-30 → 2026-06-303.5B → 5.8B (+65.6% total)+11.08%2021-09-30 → 2026-06-303.5B → 5.8B (+64.7% total)+19.99%2016-06-30 → 2026-06-30941.2M → 5.8B (+518.3% total)
Net income: +85.22%2025-06-30 → 2026-06-30870.9M → 1.6B (+85.1% total)+63.84%2023-06-30 → 2026-06-30366.5M → 1.6B (+340.0% total)+26.18%2021-09-30 → 2026-06-30534.6M → 1.6B (+201.6% total)+36.08%2016-06-30 → 2026-06-3074.1M → 1.6B (+2076.9% total)
FCF: +100.54%2025-06-30 → 2026-06-30958.1M → 1.9B (+100.4% total)+39.15%2023-06-30 → 2026-06-30712.6M → 1.9B (+169.5% total)+24.73%2021-09-30 → 2026-06-30672.8M → 1.9B (+185.5% total)+38.39%2015-12-31 → 2026-06-3063.4M → 1.9B (+2928.9% total)
Shares: +3.80%2025-06-30 → 2026-06-30195.3M → 202.7M (+3.8% total)-3.29%2023-06-30 → 2026-06-30224.1M → 202.7M (-9.5% total)-1.70%2021-06-30 → 2026-06-30220.8M → 202.7M (-8.2% total)+0.76%2016-06-30 → 2026-06-30188M → 202.7M (+7.8% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: +80.38%2025-06-30 → 2026-06-30$4.36 → $7.86 (+80.3% total)+68.95%2023-06-30 → 2026-06-30$1.63 → $7.86 (+382.5% total)+28.27%2021-09-30 → 2026-06-30$2.41 → $7.86 (+226.1% total)+35.74%2016-06-30 → 2026-06-30$0.37 → $7.86 (+2023.0% total)
Sales/share: +22.30%2025-06-30 → 2026-06-30$23.48 → $28.71 (+22.3% total)+22.34%2023-06-30 → 2026-06-30$15.68 → $28.71 (+83.1% total)+13.11%2021-09-30 → 2026-06-30$16.00 → $28.71 (+79.5% total)+19.09%2016-06-30 → 2026-06-30$5.01 → $28.71 (+473.5% total)
FCF/share: +93.20%2025-06-30 → 2026-06-30$4.91 → $9.47 (+93.1% total)+43.88%2023-06-30 → 2026-06-30$3.18 → $9.47 (+197.9% total)+27.00%2021-09-30 → 2026-06-30$3.05 → $9.47 (+211.1% total)+37.35%2015-12-31 → 2026-06-30$0.34 → $9.47 (+2697.3% total)
Book value/share: +46.58%2025-06-30 → 2026-06-30$21.36 → $31.30 (+46.5% total)+13.94%2023-06-30 → 2026-06-30$21.16 → $31.30 (+48.0% total)+18.68%2021-06-30 → 2026-06-30$13.29 → $31.30 (+135.4% total)+34.80%2016-06-30 → 2026-06-30$1.58 → $31.30 (+1880.9% total)
Price: +45.75%2025-09-18 → 2026-09-18$86.00 → $125.31 (+45.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+28.17%2023-09-18 → 2026-09-18$59.51 → $125.31 (+110.6% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+10.52%2021-09-17 → 2026-09-18$75.99 → $125.31 (+64.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+4.31%2016-09-16 → 2026-09-18$82.15 → $125.31 (+52.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +45.75%2025-09-18 → 2026-09-18$86.00 → $125.31 (+45.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+28.17%2023-09-18 → 2026-09-18$59.51 → $125.31 (+110.6% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+10.52%2021-09-17 → 2026-09-18$75.99 → $125.31 (+64.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+4.31%2016-09-16 → 2026-09-18$82.15 → $125.31 (+52.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 16.0×2016-09 118.002026-09 15.75-86.7% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 14.3×2016-09 105.732026-09 14.28-86.5% over the window
Fwd P/E: 14.0×
P/S (ttm)Market cap ÷ TTM revenue.: 4.4×2016-09 17.362026-09 4.36-74.9% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 4.0×2016-09 48.012026-09 4.00-91.7% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 13.2×2016-09 280.152026-09 13.23-95.3% over the window
EV/EBITDA (fy): 11.4×
EV/Sales (ttm): 3.7×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 7.56%2016-12 1.0%2026-06 8.3%+749.3% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 202.7M ÷ 195.3M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -3.80%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-3.80%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($13.3B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -3.80%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($25.4B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2016-06 0.0%2026-06 0.0%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($25.4B). Same caveat as the cash buyback yield.: 0.00%2016-06 0.0%2026-06 0.0%

Vs own 10Y history

P/E: 12th
P/OI: 18th
P/S: 35th
P/B: 30th
P/FCF: 3rd

Bar = where today’s multiple sits in INCY’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-09-18

-1.81%

+3.16%

+1.49%

+27.58%

YTD

+26.87%

+45.71%

+64.90%

Financial statements

Open full INCY financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	-5.94%	+0.04%
JNJ	Johnson & Johnson	-0.41%	-0.09%
ABBV	AbbVie Inc.	+1.95%	-0.02%
MRK	Merck & Co. Inc.	+8.66%	-0.19%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	-4.32%	+0.45%
TMO	Thermo Fisher Scientific Inc.	+10.60%	-1.04%
AMGN	Amgen Inc.	-9.32%	+1.55%
GILD	Gilead Sciences Inc.	+4.65%	-0.52%

Incyte Corp. (INCY) trades at $125.31 with a live price and an interactive chart covering 32+ years of daily price history, plus key valuation metrics. ChartRow also publishes INCY’s financial statements free — annual and quarterly income statement, balance sheet, and cash flow straight from SEC filings, with P/E and valuation history and dividend data. See full INCY financial statements →

INCY — Incyte Corp. price, chart and key statistics

Key stats

Price data

Volume

Fundamentals

Growth (CAGR, ttm) · 10Y

Per-share growth (CAGR, ttm) · 10Y

Valuation

Vs own 10Y history

Performance · price return · as of 2026-09-18

Financial statements

Related Healthcare